WuXi Discovery Services

Dear customers and friends, As 2024 comes to a close, I hope you and your family had a wonderful year! On behalf of my colleagues at WuXi AppTec, we deeply appreciate your trust in us. In 2025, we remain committed to supporting our customers in advancing discoveries in the pharmaceutical and life science industry and developing and delivering medicines to patients in need. I wish you and your family a joyful holiday season and a Happy New Year! Steve Yang, Ph.D. Co-CEO WuXi AppTec Please click 👇 here to view our full holiday message: https://lnkd.in/gQvpXYuF

Pancreatitis is a condition that causes inflammation of the pancreas and is one of the most common reasons for gastrointestinal hospitalizations due to its significant incidence and potential for severe complications. Existing treatments may cause side effects such as allergies and gastrointestinal injuries, and there is an urgent need for more effective therapies. To aid in the development of new drugs for the prevention and treatment of pancreatitis, WuXi Biology has established various acute and chronic pancreatitis models in mice. In our recent issue of OncoWuXi Express, we highlight a case study demonstrating how a caerulein-induced mouse model can effectively simulate the pathological characteristics of acute pancreatitis. Click 👇 this link to read our article: https://lnkd.in/gkREZ2sb #DrugDiscovery #Pancreatitis #Inflammation #cholecystokinin #CCK #caerulein

At this year’s Protein & Antibody Engineering Summit (PEGS) Europe, Crelux presented a poster highlighting its drug discovery platform for the production and characterization of protein biologics and their antigens. This platform combines construct and expression scouting, customizable high-throughput protein purification, and affinity/kinetics determination using various biophysical techniques, as well as paratope and epitope mapping through structural biology methods. This platform ensures fast turnover, high quality, adherence to high scientific standards, and is tailored for maximal flexibility to streamline the drug discovery process. Click this link 👇 to view our poster: https://lnkd.in/gK_Ps6AV #DrugDiscovery #Biotech #PEGsEurope #Biophysical #StructuralBiology #SPR #MST #CryoEM #Crystallography #ProteinPurification #Antibody

The latest edition of our WuXi Discovery Services Monthly Newsletter is here, featuring insights to keep you at the forefront of drug discovery! 🔬✨ This month’s highlights include: 🔹 Molecular Glues – Advancing protein degradation therapeutics 🔹 T-Cell Engagers – Unlocking immunotherapy potential 🔹 IBD Models – Enhancing preclinical drug development 🔹 And much more... Stay informed with the tools and strategies to help shape your work. 📩 Read the full newsletter here: 

Mutant p53 is an attractive target for anticancer drugs. Although traditionally regarded as difficult to drug, new strategies have recently become available for targeting the mutant protein. One of the most promising of these involves the use of low molecular weight compounds that promote refolding and reactivation of mutant p53 to its wild-type form. WuXi AppTec recently contributed to a research article in ACS Med. Chem. Letters describing chemistry efforts that led to the discovery of PC14586, an orally available small molecule "structural corrector" that is designed to bind selectively to the pocket within the p53 Y220C mutant protein. In mouse models with established human tumor xenografts harboring the p53 Y220C mutation, this compound demonstrated tumor inhibition and regression at well-tolerated doses. Click 👇 this link to access the FULL article: https://lnkd.in/gSdJry4u #DrugDiscovery #p53 #tumorsuppressor #apoptosis #Y220C

There's still time to register for our upcoming webinar, where we will discuss essential strategies and methodologies for accelerating the preclinical development of antibody-drug conjugates (ADCs). ADCs hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges for project teams. This webinar will introduce a comprehensive approach for evaluating ADC efficacy, resistance, and immunogenicity that addresses both antibody-specific and payload-specific mechanisms through various multi-dimensional assays. Don’t miss your chance to ask questions to our experts! Register now by clicking 👇 this link: https://lnkd.in/g6fnMGbf

WuXi Biology has recently launched an upgraded edition of its DNA-encoded library kit - “DEL SE 2.0”. This enhanced version significantly increases bioactive space coverage, offering access to 2 billion open-source structures, including 10 newly added 2-cycle libraries that bring in more drug-like molecules. For those exploring new modalities or facing targets with poor druggability, a new cyclic peptide DEL library is available as an optional add-on. Furthermore, to ensure seamless DEL screening across various scenarios, WuXi Biology provides complimentary support tools, including refined screening protocols, an automated DEL decoder, and the intelligent data analyzer ‘Hit Copilot’. DEL SE 2.0 is available starting from a single tube, providing an innovative and affordable solution for new molecule discovery to all researchers. Unlock your gradient discounts to support multiple research projects by contacting us at [email protected].

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment. To support the discovery of novel CDK inhibitors, the WuXi AppTec Discovery Biology Structural Biology platform provides a wide range of biophysical, X-ray crystallography, and cryo-EM services for a variety of CDK family members, including CDK4, CDK6 and CDK7. With decades of experience in structural biology and state-of-the-art infrastructure in Munich (Germany) and Suzhou (China), we are the ideal partner for your drug discovery program.   Click this link 👇 to learn more about our structural biology services. https://lnkd.in/ems4D6NH #Biophysical #CDK #Cyclin #Crystallography #StructuralBiology #SPR #MST #NanoDSF

Psoriasis is a chronic autoimmune skin disease characterized by abnormal keratinocyte proliferation and infiltration of inflammatory cells. The absence of a suitable animal model that accurately mimics the complex phenotype of psoriasis in humans has hindered the development of promising therapeutics to treat this condition. At SITC 2024, WuXi AppTec presented a poster showcasing the use of imiquimod to induce psoriasis-like biological and pathological symptoms in NHPs, aiming to facilitate the efficacy evaluation of potential psoriasis treatments. The authors demonstrate that this NHP model can replicate key pathological features of human psoriasis, including clinical appearance, histological changes, and inflammatory cytokine profiles. Click 👇 this link to download our poster: https://lnkd.in/gTczPf33 #DrugDiscovery #Biotech #Imiquimod #Psoriasis #Keratinocyte

Vitiligo is an autoimmune disorder characterized by the progressive destruction of melanocytes in the skin. This condition is driven by the infiltration of endogenous autoreactive CD8+ T cells which target and destroy melanocytes, resulting in the clinical manifestation of skin depigmentation. As a common acquired skin disease with no highly effective treatments, there is an urgent need for the development of more effective therapies. Recent studies have shown that NLRP3 inhibitors can reduce CD8+ T cell activity, highlighting NLRP3 as a potential target for treating vitiligo. At SITC 2024, WuXi AppTec presented a poster showcasing the successful establishment of an in vivo mouse model to support research in this area. The authors demonstrate that treatment with an NLRP3 inhibitor effectively reversed the symptoms of melanoma-induced vitiligo in mice. Click 👇 this link to download our poster: https://lnkd.in/g7CtHXJk #DrugDiscovery #CD8Tcells #NLRP3 #Vitiligo #Depigmentation #Melanocytes